Dr. Karen Antman, an internationally recognized expert on breast cancer, mesotheliomas and sarcomas, is Provost of the Medical Campus and Dean of Boston University Chobanian & Avedisian School of Medicine since 2005. Dr. Antman previously served as Deputy Director for Translational and Clinical Sciences at the National Cancer Institute of the National Institutes of Health (NIH) (2004-5) and before that as Wu Professor of Medicine and Pharmacology and Director of the Herbert Irving Comprehensive Cancer Center at Columbia University College of Physicians and Surgeons, where she also co-directed the cancer care service line at New York Presbyterian Hospital. Dr. Antman was voted 1993 Senior Faculty Teacher of the Year by medical residents. She also served on the faculty of Harvard Medical School from 1979 to 1993, and had hospital appointments at Brigham and Women’s Hospital and Dana-Farber Cancer Institute in Boston.
Based on her group’s translational research, Dr Antman developed now standard regimens for the treatment of sarcomas and mesotheliomas as well as regimens for breast cancer and supportive care of patients receiving chemotherapy including pharmacology, growth factors and mobilization of peripheral blood derived stem cells for blood and marrow transplant. Dr. Antman also is outspoken on public health policy issues. She has written extensively about impediments to clinical research on cancer, and she has testified before Congress on the need for federal research dollars to support cancer research with articles in the medical literature (as well as Vogue and Readers Digest). She has written more than 300 journal papers and edited five textbooks and monographs, many with multiple editions.
She is a member of PBK and the Institute of Medicine. She has served as President of the American Society of Clinical Oncology in 1994-5, the American Society of Blood and Marrow Transplant in 1996-7, and the American Association for Cancer Research in 2003-4.
She has more than 300 publications and is the editor of 5 textbooks and monographs (Asbestos related malignancies, Sarcomas of Bone and Soft Tissue, High-dose cancer therapy: pharmacology, hematopoietins and stem cells (3 editions), and Molecular Targeting in Oncology).
She serves on the Administration Board of the American Association of Medical Colleges Council of Deans, the Journal of the American Medical Association Oversight Committee, the International Editorial Board of Lancet, and on the board of the Educational Commission for Foreign Medical Graduates (ECFMG). She has served as an associate editor of the New England Journal of Medicine, and on the Council of the National Institutes of Health’s Fogarty International Center.
She has published reviews and editorials on medical policy and the impact of research funding and managed care on American clinical research and testified before congressional subcommittees on eight occasions on National Institutes of Health (NIH) appropriations and medical policy.
Diversity, Equity, Inclusion and Accessibility
Diversity and inclusion were core tenants of the small rural Mennonite and Quaker community where I grew up. (The community was deeply suspicious of words, and focused on actions.)
I attended Muhlenberg College during the Civil Rights movement and as the president of student council, participating in a national student convention with the Vietnam war and civil rights as key issues. On May 4, 1970, members of the Ohio National Guard fired into a crowd of Kent State University demonstrators, killing four and wounding nine Kent State students, triggering a nationwide student strike. Hundreds of colleges and universities closed abruptly, including mine ending our senior year classes. While at college, I spent a summer on an exchange program to Prague, Czechoslovakia and Eastern Europe including Hungary, Romania and Yugoslavia.
My medical school, Columbia, was located in and served the Spanish Harlem community of New York City; Harlem Hospital was also our affiliate. Later as faculty and Cancer Center director, I directed a breast cancer clinic that served our predominately Black and Latin community, and provided Spanish speaking nurses and navigators and language congruent educational materials. Our initiatives led to only a one percent disparity between mammography rates of our Black and White patients. We had not yet reached the same levels for our Latin and Asian population. I organized and led a national symposia on addressing breast cancer disparities. (Antman et al, Reducing Disparities in Breast Cancer Survival: A Columbia University and Avon Breast Cancer Research and Care Network Symposium, Breast Cancer Research & Treatment, 2002, 75:269-80.) I also served as the Wu professor of Oncology at Columbia and thus traveled frequently to universities in China (and Japan).
At the National Cancer Institute, where I served as Deputy Director for Translational and Clinical Science, my portfolio included the NCI Center to Reduce Cancer Health Disparities (CRCHD), which provided minority training programs and grant supplements. While at the NCI, I served on the advisory Board of the King Hussein Cancer Center in Aman, Jordan where I learned about care delivery and Muslim social customs.
The position as dean at Boston University School of Medicine was attractive specifically because of our history and current mission to serve our community, address health disparities and recruit diverse trainees in science and medicine. At BU, I have traveled with BU colleagues to medical schools and hospitals in Dubai, Abu Dhabi ad Saudi Arabia as well as India and China. I also served on the NIH Fogarty International Advisory Board, developing strategy to increase biomedical research internationally and on the Educational Commission for Foreign Medical Graduates, which supports physicians in the United States from other countries.
At BU we have a vibrant community of faculty, staff and students who came from many cultures and religions. My goal as dean is to foster a campus community where all members feel a sense of belonging and are appreciated for their unique identities and contributions. A campus community where we collectively work to remove barriers so that our faculty, students, trainees, and staff realize their full potential and enact social change. I am committed to a campus culture that provides and promotes diverse, equitable, inclusive, and accessible education, research and health care for our local community and beyond.
Dean
Boston University Chobanian & Avedisian School of Medicine
Dean’s Office
Professor
Boston University Chobanian & Avedisian School of Medicine
Medicine
Hematology & Medical Oncology
Graduate Faculty (Primary Mentor of Grad Students)
Boston University Chobanian & Avedisian School of Medicine, Graduate Medical Sciences
This tab shows grant data from BMC Sponsored Research. It includes:
- Grant title
- Project period and this person’s role on the grant
- PI name, if this person is not the PI (the name will link if PI has a BU Profile)
- Funding source(s). An arrow indicates the flow of funding if multiple sponsors.
- Some grants will show an agency award/project number, and may be a link.
- Data is sorted by project end date, and updated monthly.
This tab shows grant data from BU Sponsored Research. It includes:
- Grant title
- Project period and this person’s role on the grant
- PI name, if this person is not the PI (the name will link if PI has a BU Profile)
- Funding source(s). An arrow indicates the flow of funding if multiple sponsors.
- Some grants will show an agency award/project number, and may be a link.
- Data is sorted by project end date, and updated monthly.
This tab shows grant data that did not automatically get imported into Profiles
from BU or BMC sources.
- Grant title
- Project period and this person’s role on the grant
- PI name, if this person is not the PI (the name will link if PI has a BU Profile)
- Funding source(s). An arrow indicates the flow of funding if multiple sponsors.
- Some grants will show an agency award/project number, and may be a link.
- Data is sorted by project end date, and updated monthly.
This tab shows grant data from the Boston VA. We are only showing grant title, and only for people in the role of PI.
Identifying medical researchers working on early-stage, future-focused brain science to become Toffler Scholars12/01/2020 - 08/31/2025 (PI)
Karen Toffler Charitable Trust
Showing 10 of 49 results.
Show All Results
Publications listed below are automatically derived from MEDLINE/PubMed and other
sources, which might result in incorrect or missing publications. Faculty can
login
to make corrections and additions.
-
Collins ME, Rum S, Wheeler J, Antman K, Brem H, Carrese J, Glennon M, Kahn J, Ohman EM, Jagsi R, Konrath S, Tovino S, Wright S, Sugarman J. Ethical Issues and Recommendations in Grateful Patient Fundraising and Philanthropy. Acad Med. 2018 11; 93(11):1631-1637. PMID: 30024472; PMCID: PMC6211779; DOI: 10.1097/ACM.0000000000002365;
-
Kerschner JE, Hedges JR, Antman K, Abraham E, Colón Negrón E, Jameson JL. Recommendations to Sustain the Academic Mission Ecosystem at U.S. Medical Schools. Acad Med. 2018 07; 93(7):985-989. PMID: 29538107; PMCID: PMC6019606; DOI: 10.1097/ACM.0000000000002212;
-
Antman K. Building on #MeToo to Enhance the Learning Environment for US Medical Schools. JAMA. 2018 May 01; 319(17):1759-1760. PMID: 29610835
-
Bharel M, Antman K, Berman H, Dimitri D, Flier J, Flotte T. In Reply to Manion and Khan. Acad Med. 2017 06; 92(6):725-726.View Related Profiles. PMID: 28557909
-
Antman KH, Berman HA, Flotte TR, Flier J, Dimitri DM, Bharel M. Developing Core Competencies for the Prevention and Management of Prescription Drug Misuse: A Medical Education Collaboration in Massachusetts. Acad Med. 2016 Oct; 91(10):1348-1351.View Related Profiles. PMID: 27532868
-
Tefferi A, Kantarjian H, Rajkumar SV, Baker LH, Abkowitz JL, Adamson JW, Advani RH, Allison J, Antman KH, Bast RC, Bennett JM, Benz EJ, Berliner N, Bertino J, Bhatia R, Bhatia S, Bhojwani D, Blanke CD, Bloomfield CD, Bosserman L, Broxmeyer HE, Byrd JC, Cabanillas F, Canellos GP, Chabner BA, Chanan-Khan A, Cheson B, Clarkson B, Cohn SL, Colon-Otero G, Cortes J, Coutre S, Cristofanilli M, Curran WJ, Daley GQ, DeAngelo DJ, Deeg HJ, Einhorn LH, Erba HP, Esteva FJ, Estey E, Fidler IJ, Foran J, Forman S, Freireich E, Fuchs C, George JN, Gertz MA, Giralt S, Golomb H, Greenberg P, Gutterman J, Handin RI, Hellman S, Hoff PM, Hoffman R, Hong WK, Horowitz M, Hortobagyi GN, Hudis C, Issa JP, Johnson BE, Kantoff PW, Kaushansky K, Khayat D, Khuri FR, Kipps TJ, Kripke M, Kyle RA, Larson RA, Lawrence TS, Levine R, Link MP, Lippman SM, Lonial S, Lyman GH, Markman M, Mendelsohn J, Meropol NJ, Messinger Y, Mulvey TM, O'Brien S, Perez-Soler R, Pollock R, Prchal J, Press O, Radich J, Rai K, Rosenberg SA, Rowe JM, Rugo H, Runowicz CD, Sandmaier BM, Saven A, Schafer AI, Schiffer C, Sekeres MA, Silver RT, Siu LL, Steensma DP, Stewart FM, Stock W, Stone R, Storb R, Strong LC, Tallman MS, Thompson M, Ueno NT, Van Etten RA, Vose JM, Wiernik PH, Winer EP, Younes A, Zelenetz AD, LeMaistre CA. In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc. 2015 Aug; 90(8):996-1000. PMID: 26211600; PMCID: PMC5365030; DOI: 10.1016/j.mayocp.2015.06.001;
-
Levine AS, Alpern RJ, Andrews NC, Antman K, Balser JR, Berg JM, Davis PB, Fitz JG, Golden RN, Goldman L, Jameson JL, Lee VS, Polonsky KS, Rappley MD, Reece EA, Rothman PB, Schwinn DA, Shapiro LJ, Spiegel AM. Research in academic medical centers: two threats to sustainable support. Sci Transl Med. 2015 May 27; 7(289):289fs22. PMID: 26019216; DOI: 10.1126/scitranslmed.aac5200;
-
Stiff PJ, Agovi MA, Antman KH, Blaise D, Camitta BM, Cairo MS, Childs RW, Edwards JR, Gale RP, Hale GA, Lazarus HM, Arora M. High-dose chemotherapy with blood or bone marrow transplants for rhabdomyosarcoma. Biol Blood Marrow Transplant. 2010 Apr; 16(4):525-32. PMID: 19961947; PMCID: PMC2838953; DOI: 10.1016/j.bbmt.2009.11.020;
-
Chabot JA, Tsai WY, Fine RL, Chen C, Kumah CK, Antman KA, Grann VR. Pancreatic proteolytic enzyme therapy compared with gemcitabine-based chemotherapy for the treatment of pancreatic cancer. J Clin Oncol. 2010 Apr 20; 28(12):2058-63. PMID: 19687327; PMCID: PMC2860407; DOI: 10.1200/JCO.2009.22.8429;
-
Duley L, Antman K, Arena J, Avezum A, Blumenthal M, Bosch J, Chrolavicius S, Li T, Ounpuu S, Perez AC, Sleight P, Svard R, Temple R, Tsouderous Y, Yunis C, Yusuf S. Specific barriers to the conduct of randomized trials. Clin Trials. 2008; 5(1):40-8. PMID: 18283079; DOI: 10.1177/1740774507087704;
Showing 10 of 200 results.
Show More
-
-
Hassan R, Alexander R, Antman K, Boffetta P, Churg A, Coit D, Hausner P, Kennedy R, Kindler H, Metintas M, Mutti L, Onda M, Pass H, Premkumar A, Roggli V, Sterman D, Sugarbaker P, Taub R, Verschraegen C. Current treatment options and biology of peritoneal mesothelioma: meeting summary of the first NIH peritoneal mesothelioma conference. Ann Oncol. 2006 Nov; 17(11):1615-9. PMID: 16600983
-
Antman K, Hassan R, Eisner M, Ries LA, Edwards BK. Update on malignant mesothelioma. Oncology (Williston Park). 2005 Sep; 19(10):1301-9; discussion 1309-10, 1313-6. PMID: 16285225
-
Zalupski MM, Rankin C, Ryan JR, Lucas DR, Muler J, Lanier KS, Budd GT, Biermann JS, Meyers FJ, Antman K. Adjuvant therapy of osteosarcoma--A Phase II trial: Southwest Oncology Group study 9139. Cancer. 2004 Feb 15; 100(4):818-25. PMID: 14770440
-
Talbot SM, Rankin C, Taub RN, Balcerzak SP, Bhoopalam N, Chapman RA, Baker LH, Middleman EL, Antman KH. High-dose ifosfamide with mesna and granulocyte-colony-stimulating factor (recombinant human G-CSF) in patients with unresectable malignant mesothelioma. Cancer. 2003 Jul 15; 98(2):331-6. PMID: 12872353
-
Rizzo JD, Williams S, Wu JT, Pecora AL, Lazarus HM, Bolwell B, Fields KK, Gale RP, Elfenbein G, Horowitz MM, Antman KH. Syngeneic hematopoietic stem cell transplantation for women with metastatic breast cancer. Bone Marrow Transplant. 2003 Jul; 32(2):151-5. PMID: 12838279
-
Tiersten AD, Nelsen C, Talbot S, Vahdat L, Fine R, Troxel A, Brafman L, Shriberg L, Antman K, Petrylak DP. A phase II trial of docetaxel and estramustine in patients with refractory metastatic breast carcinoma. Cancer. 2003 Feb 1; 97(3):537-44. PMID: 12548594
-
Antman K, Abraido-Lanza AF, Blum D, Brownfield E, Cicatelli B, Debor MD, Emmons K, Fitzgibbon M, Gapstur SM, Gradishar W, Hiatt RA, Hubbell FA, Joe AK, Klassen AC, Lee NC, Linden HM, McMullin J, Mishra SI, Neuhaus C, Olopade FI, Walas K. Reducing disparities in breast cancer survival: a Columbia University and Avon Breast Cancer Research and Care Network Symposium. Breast Cancer Res Treat. 2002 Oct; 75(3):269-80. PMID: 12353816
-
Vahdat LT, Balmaceda C, Papadopoulos K, Frederick D, Donovan D, Sharpe E, Kaufman E, Savage D, Tiersten A, Nichols G, Haythe J, Troxel A, Antman K, Hesdorffer CS. Phase II trial of sequential high-dose chemotherapy with paclitaxel, melphalan and cyclophosphamide, thiotepa and carboplatin with peripheral blood progenitor support in women with responding metastatic breast cancer. Bone Marrow Transplant. 2002 Aug; 30(3):149-55. PMID: 12189532
-
Savage DG, Antman KH. Imatinib mesylate--a new oral targeted therapy. N Engl J Med. 2002 Feb 28; 346(9):683-93. PMID: 11870247
-
Budd GT, Rankin C, Hutchins LF, Wong L, Petruska PJ, Antman K. Phase II trial of topotecan by continuous infusion in patients with advanced soft tissue sarcomas, a SWOG study. Southwest Oncology Group. Invest New Drugs. 2002 Feb; 20(1):129-32. PMID: 12003189
-
Berry DA, Broadwater G, Klein JP, Antman K, Aisner J, Bitran J, Costanza M, Freytes CO, Stadtmauer E, Gale RP, Henderson IC, Lazarus HM, McCarthy PL, Norton L, Parnes H, Pecora A, Perry MC, Rowlings P, Spitzer G, Horowitz MM. High-dose versus standard chemotherapy in metastatic breast cancer: comparison of Cancer and Leukemia Group B trials with data from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol. 2002 Feb 1; 20(3):743-50. PMID: 11821456
-
Antman K. Randomized trials of high-dose chemotherapy in breast cancer: fraud, the press and the data (or lessons learned in medical policy governing clinical research). Trans Am Clin Climatol Assoc. 2002; 113:56-66; discussion 66-7. PMID: 12053718; PMCID: PMC2194463
-
Antman KH. New biology and therapies in soft tissue sarcomas. Biomed Pharmacother. 2001 Nov; 55(9-10):553-7. PMID: 11769966
-
Antman K, Benson MC, Chabot J, Cobrinik D, Grann VR, Jacobson JS, Joe AK, Katz AE, Kelly K, Neugut AI, Russo D, Tiersten A, Weinstein IB. Complementary and alternative medicine: the role of the cancer center. J Clin Oncol. 2001 Sep 15; 19(18 Suppl):55S-60S. PMID: 11560974
-
Scully RE, Antman KH. Protocol for the examination of specimens from patients with tumors of the peritoneum: a basis for checklists. Arch Pathol Lab Med. 2001 Sep; 125(9):1174-6. PMID: 11520266
-
Vahdat L, Papadopoulos K, Lange D, Leuin S, Kaufman E, Donovan D, Frederick D, Bagiella E, Tiersten A, Nichols G, Garrett T, Savage D, Antman K, Hesdorffer CS, Balmaceda C. Reduction of paclitaxel-induced peripheral neuropathy with glutamine. Clin Cancer Res. 2001 May; 7(5):1192-7. PMID: 11350883
-
Antman KH. Randomized trials of high dose chemotherapy for breast cancer. Biochim Biophys Acta. 2001 Mar 21; 1471(3):M89-98. PMID: 11250065
-
Antman K, Lagakos S, Drazen J. Designing and funding clinical trials of novel therapies. N Engl J Med. 2001 Mar 8; 344(10):762-3.View Related Profiles. PMID: 11236782
-
Antman KH. A critique of the eleven randomised trials of high-dose chemotherapy for breast cancer. Eur J Cancer. 2001 Jan; 37(2):173-9. PMID: 11166143
-
Antman KH. Introduction: the history of arsenic trioxide in cancer therapy. Oncologist. 2001; 6 Suppl 2:1-2. PMID: 11331433
-
Antman KH. Overview of the six available randomized trials of high-dose chemotherapy with blood or marrow transplant in breast cancer. J Natl Cancer Inst Monogr. 2001; (30):114-6. PMID: 11773303
-
Grann VR, Sundararajan V, Jacobson JS, Whang W, Heitjan DF, Antman KH, Neugut AI. Decision analysis of tamoxifen for the prevention of invasive breast cancer. Cancer J. 2000 May-Jun; 6(3):169-78. PMID: 10882333
-
Antman K, Chang Y. Kaposi's sarcoma. N Engl J Med. 2000 Apr 6; 342(14):1027-38. PMID: 10749966
-
Grann VR, Jacobson JS, Whang W, Hershman D, Heitjan DF, Antman KH, Neugut AI. Prevention with tamoxifen or other hormones versus prophylactic surgery in BRCA1/2-positive women: a decision analysis. Cancer J Sci Am. 2000 Jan-Feb; 6(1):13-20. PMID: 10696733
-
Moslehi R, Russo D, Phelan C, Jack E, Antman K, Narod S. An unaffected individual from a breast/ovarian cancer family with germline mutations in both BRCA1 and BRCA2. Clin Genet. 2000 Jan; 57(1):70-3. PMID: 10733239
-
Antman KH. High-dose chemotherapy in breast cancer: the end of the beginning? Biol Blood Marrow Transplant. 2000; 6(5):469-75. PMID: 11063376
-
Antman KH, Heitjan DF, Hortobagyi GN. High-dose chemotherapy for breast cancer. JAMA. 1999 Nov 10; 282(18):1701-3. PMID: 10568629
-
Antman KH. Critique of the high-dose chemotherapy studies in breast cancer: a positive look at the data. J Clin Oncol. 1999 Nov; 17(11 Suppl):30-4. PMID: 10630259
-
Rowlings PA, Williams SF, Antman KH, Fields KK, Fay JW, Reed E, Pelz CJ, Klein JP, Sobocinski KA, Kennedy MJ, Freytes CO, McCarthy PL, Herzig RH, Stadtmauer EA, Lazarus HM, Pecora AL, Bitran JD, Wolff SN, Gale RP, Armitage JO, Vaughan WP, Spitzer G, Horowitz MM. Factors correlated with progression-free survival after high-dose chemotherapy and hematopoietic stem cell transplantation for metastatic breast cancer. JAMA. 1999 Oct 13; 282(14):1335-43. PMID: 10527180
-
Papadopoulos KP, Balmaceda C, Fetell M, Kaufman E, Vahdat LT, Bruce J, Sisti M, Isaacson S, De LaPaz R, Savage DG, Troxel A, Antman KH, Hesdorffer CS. A phase I study of high-dose BCNU, etoposide and escalating-dose thiotepa (BTE) with hematopoietic progenitor cell support in adults with recurrent and high-risk brain tumors. J Neurooncol. 1999 Sep; 44(2):155-62. PMID: 10619499
-
Antman K, Tiersten A. High-dose chemotherapy for breast cancer: evolving data. Oncology (Williston Park). 1999 Sep; 13(9):1215-9. PMID: 10509318
-
Papadopoulos KP, Ayello J, Reiss RF, Troxel A, Kaufman E, Vahdat LT, Antman KH, Hesdorffer CS. CD34+ cell dose requirements for rapid engraftment in a sequential high-dose chemotherapy regimen of paclitaxel, melphalan, and cyclophosphamide, thiotepa, and carboplatin (CTCb) with PBPC support in metastatic breast cancer. J Hematother Stem Cell Res. 1999 Aug; 8(4):357-63. PMID: 10634173
-
McCarthy P, Hurd D, Rowlings P, Crump M, Gale R, Lazarus H, Vaughan W, Weinberger B, Wiemann M, Freytes C, Cirenza E, Antman K. Autotransplants in men with breast cancer. ABMTR Breast Cancer Working Committee. Autologous Blood and Marrow Transplant Registry. Bone Marrow Transplant. 1999 Aug; 24(4):365-8. PMID: 10467324
-
Antman K, Shea S. Screening mammography under age 50. JAMA. 1999 Apr 28; 281(16):1470-2. PMID: 10227298
-
Elias A, Ibrahim J, Skarin AT, Wheeler C, McCauley M, Ayash L, Richardson P, Schnipper L, Antman KH, Frei E. Dose-intensive therapy for limited-stage small-cell lung cancer: long-term outcome. J Clin Oncol. 1999 Apr; 17(4):1175. PMID: 10561176
-
Grann VR, Whang W, Jacobson JS, Heitjan DF, Antman KH, Neugut AI. Benefits and costs of screening Ashkenazi Jewish women for BRCA1 and BRCA2. J Clin Oncol. 1999 Feb; 17(2):494-500. PMID: 10080590
-
Shipp MA, Abeloff MD, Antman KH, Carroll G, Hagenbeek A, Loeffler M, Montserrat E, Radford JA, Salles G, Schmitz N, Symann M, Armitage JO, Philip T, Coiffier B. International Consensus Conference on High-Dose Therapy with Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin's Lymphomas: report of the jury. J Clin Oncol. 1999 Jan; 17(1):423-9. PMID: 10458261
-
Shipp MA, Abeloff MD, Antman KH, Carroll G, Hagenbeek A, Loeffler M, Montserrat E, Radford JA, Salles G, Schmitz N, Symann M, Armitage JO, Coiffier B, Philip T. International Consensus Conference on high-dose therapy with hematopoietic stem-cell transplantation in aggressive non-Hodgkin's lymphomas: report of the jury. Ann Oncol. 1999 Jan; 10(1):13-9. PMID: 10076716
-
Papadopoulos KP, Garvin JH, Fetell M, Vahdat LT, Garrett TJ, Savage DG, Balmaceda C, Bruce J, Sisti M, Isaacson S, De LaPaz R, Hawks R, Bagiella E, Antman KH, Hesdorffer CS. High-dose thiotepa and etoposide-based regimens with autologous hematopoietic support for high-risk or recurrent CNS tumors in children and adults. Bone Marrow Transplant. 1998 Oct; 22(7):661-7. PMID: 9818693
-
Vahdat LT, Papadopoulos K, Balmaceda C, McGovern T, Dunleavy J, Kaufman E, Fung B, Garrett T, Savage D, Tiersten A, Ayello J, Bagiella E, Heitjan D, Antman K, Hesdorffer C. Phase I trial of sequential high-dose chemotherapy with escalating dose paclitaxel, melphalan, and cyclophosphamide, thiotepa, and carboplatin with peripheral blood progenitor support in women with responding metastatic breast cancer. Clin Cancer Res. 1998 Jul; 4(7):1689-95. PMID: 9676843
-
Frank TS, Manley SA, Olopade OI, Cummings S, Garber JE, Bernhardt B, Antman K, Russo D, Wood ME, Mullineau L, Isaacs C, Peshkin B, Buys S, Venne V, Rowley PT, Loader S, Offit K, Robson M, Hampel H, Brener D, Winer EP, Clark S, Weber B, Strong LC, Thomas A, et al. Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. J Clin Oncol. 1998 Jul; 16(7):2417-25. PMID: 9667259
-
Elias AD, Wheeler C, Ayash LJ, Schwartz G, Ibrahim J, Mills L, McCauley M, Coleman N, Warren D, Schnipper L, Antman KH, Teicher BA, Frei E. Dose escalation of the hypoxic cell sensitizer etanidazole combined with ifosfamide, carboplatin, etoposide, and autologous hematopoietic stem cell support. Clin Cancer Res. 1998 Jun; 4(6):1443-9. PMID: 9626461
-
Antman K, Crowley J, Balcerzak SP, Kempf RA, Weiss RB, Clamon GH, Baker LH. A Southwest Oncology Group and Cancer and Leukemia Group B phase II study of doxorubicin, dacarbazine, ifosfamide, and mesna in adults with advanced osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma. Cancer. 1998 Apr 1; 82(7):1288-95. PMID: 9529020
-
Ayash LJ, Elias A, Ibrahim J, Schwartz G, Wheeler C, Reich E, Lynch C, Warren D, Shapiro C, Richardson P, Hurd D, Schnipper L, Frei E, Antman K. High-dose multimodality therapy with autologous stem-cell support for stage IIIB breast carcinoma. J Clin Oncol. 1998 Mar; 16(3):1000-7. PMID: 9508183
-
Grann VR, Panageas KS, Whang W, Antman KH, Neugut AI. Decision analysis of prophylactic mastectomy and oophorectomy in BRCA1-positive or BRCA2-positive patients. J Clin Oncol. 1998 Mar; 16(3):979-85. PMID: 9508180
-
Hesdorffer C, Ayello J, Ward M, Kaubisch A, Vahdat L, Balmaceda C, Garrett T, Fetell M, Reiss R, Bank A, Antman K. Phase I trial of retroviral-mediated transfer of the human MDR1 gene as marrow chemoprotection in patients undergoing high-dose chemotherapy and autologous stem-cell transplantation. J Clin Oncol. 1998 Jan; 16(1):165-72. PMID: 9440739
-
Chen CS, Seidel K, Armitage JO, Fay JW, Appelbaum FR, Horowitz MM, Shpall EJ, Weiden PL, Antman KS, Champlin RE, Kersey JH, Sullivan KM. Safeguarding the administration of high-dose chemotherapy: a national practice survey by the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 1997 Dec; 3(6):331-40. PMID: 9502301
-
Vahdat L, Antman K. High-dose chemotherapy with autologous stem cell support for breast cancer. Curr Opin Hematol. 1997 Nov; 4(6):381-9. PMID: 9358993
-
Taub RN, Antman KH. Chemotherapy for malignant mesothelioma. Semin Thorac Cardiovasc Surg. 1997 Oct; 9(4):361-6. PMID: 9352953
-
Antman KH. Adjuvant therapy of sarcomas of soft tissue. Semin Oncol. 1997 Oct; 24(5):556-60. PMID: 9344322
-
Neugut AI, Ahsan H, Antman KH. Incidence of malignant pleural mesothelioma after thoracic radiotherapy. Cancer. 1997 Sep 1; 80(5):948-50. PMID: 9307196
-
Wheeler C, Eickhoff C, Elias A, Ibrahim J, Ayash L, McCauley M, Mauch P, Schwartz G, Eder JP, Mazanet R, Ferrara J, Rimm IJ, Guinan E, Bierer B, Gilliland G, Churchill WH, Ault K, Parsons S, Antman K, Schnipper L, Tepler I, Gaynes L, Frei E, Kadin M, Antin J. High-dose cyclophosphamide, carmustine, and etoposide with autologous transplantation in Hodgkin's disease: a prognostic model for treatment outcomes. Biol Blood Marrow Transplant. 1997 Jun; 3(2):98-106.View Related Profiles. PMID: 9267670
-
Yogelzang NJ, Herndon JE, Cirrincione C, Harmon DC, Antman KH, Corson JM, Suzuki Y, Citron ML, Green MR. Dihydro-5-azacytidine in malignant mesothelioma. A phase II trial demonstrating activity accompanied by cardiac toxicity. Cancer and Leukemia Group B. Cancer. 1997 Jun 1; 79(11):2237-42. PMID: 9179072
-
Antman KH, Rowlings PA, Vaughan WP, Pelz CJ, Fay JW, Fields KK, Freytes CO, Gale RP, Hillner BE, Holland HK, Kennedy MJ, Klein JP, Lazarus HM, McCarthy PL, Saez R, Spitzer G, Stadtmauer EA, Williams SF, Wolff S, Sobocinski KA, Armitage JO, Horowitz MM. High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. J Clin Oncol. 1997 May; 15(5):1870-9. PMID: 9164197
-
Pandita TK, Benvenuto JA, Shay JW, Pandita RK, Rakovitch E, Geard CR, Antman KH, Newman RA. Effect of penclomedine (NSC-338720) on telomere fusions, chromatin blebbing, and cell viability with and without telomerase activity and abrogated p53 function. Biochem Pharmacol. 1997 Feb 7; 53(3):409-15. PMID: 9065745
-
Papadopoulos KP, Ayello J, Tugulea S, Heitjan DF, Williams C, Reiss RF, Vahdat LT, Suciu-Foca N, Antman KH, Hesdorffer CS. Harvest quality and factors affecting collection and engraftment of CD34+ cells in patients with breast cancer scheduled for high-dose chemotherapy and peripheral blood progenitor cell support. J Hematother. 1997 Feb; 6(1):61-8. PMID: 9112219
-
Renshaw AA, Dean BR, Antman KH, Sugarbaker DJ, Cibas ES. The role of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma. Chest. 1997 Jan; 111(1):106-9. PMID: 8996002
-
Keohan ML, Grever MR, Balcerzak SP, Antman K. A phase II Southwest Oncology Group study of cisplatin and continuous infusion vinblastine in the treatment of advanced soft tissue sarcoma. Invest New Drugs. 1997; 15(3):255-6. PMID: 9387048
-
Ayash LJ, Elias A, Schwartz G, Wheeler C, Ibrahim J, Teicher BA, Reich E, Warren D, Lynch C, Richardson P, Schnipper L, Frei E, Antman K. Double dose-intensive chemotherapy with autologous stem-cell support for metastatic breast cancer: no improvement in progression-free survival by the sequence of high-dose melphalan followed by cyclophosphamide, thiotepa, and carboplatin. J Clin Oncol. 1996 Nov; 14(11):2984-92. PMID: 8918496
-
Ross AA, Layton TJ, Ostrander AB, Passos-Coelho JL, Davis JM, Huelskamp AM, Noga SJ, Davidson NE, Kennedy MJ, Cooper BW, Gerson SL, Lazarus HM, Holland K, Gluck S, Moss TJ, Kaubish A, Vahdat L, Antman K. Comparative analysis of breast cancer contamination in mobilized and nonmobilized hematopoietic grafts. J Hematother. 1996 Oct; 5(5):549-52. PMID: 8938527
-
Antman K. When are bone marrow transplants considered? Sci Am. 1996 Sep; 275(3):124-5. PMID: 8701281
-
Weissmann LB, Corson JM, Neugut AI, Antman KH. Malignant mesothelioma following treatment for Hodgkin's disease. J Clin Oncol. 1996 Jul; 14(7):2098-100. PMID: 8683242
-
Antman K. Presidential address. May 22, 1995 Thirty-First Annual Meeting of the American Society of Clinical Oncology. J Clin Oncol. 1995 Dec; 13(12):2980-9. PMID: 8523064
-
Vahdat L, Antman K. High-dose therapy for breast cancer. Blood Rev. 1995 Sep; 9(3):191-200. PMID: 8563521
-
Ayash LJ, Wheeler C, Fairclough D, Schwartz G, Reich E, Warren D, Schnipper L, Antman K, Frei E, Elias A. Prognostic factors for prolonged progression-free survival with high-dose chemotherapy with autologous stem-cell support for advanced breast cancer. J Clin Oncol. 1995 Aug; 13(8):2043-9. PMID: 7636547
-
Wright JE, Elias A, Tretyakov O, Holden S, Andersen J, Wheeler C, Schwartz G, Antman K, Rosowsky A, Frel E, et al. High-dose ifosfamide, carboplatin, and etoposide pharmacokinetics: correlation of plasma drug levels with renal toxicity. Cancer Chemother Pharmacol. 1995; 36(4):345-51. PMID: 7628055
-
Lew MA, Kehoe K, Ritz J, Antman KH, Nadler L, Kalish LA, Finberg R. Ciprofloxacin versus trimethoprim/sulfamethoxazole for prophylaxis of bacterial infections in bone marrow transplant recipients: a randomized, controlled trial. J Clin Oncol. 1995 Jan; 13(1):239-50. PMID: 7799026
-
Elias AD, Ayash LJ, Wheeler C, Schwartz G, Tepler I, McCauley M, Mazanet R, Schnipper L, Frei E, Antman KH. High-dose ifosfamide/carboplatin/etoposide with autologous hematopoietic stem cell support: safety and future directions. Semin Oncol. 1994 Oct; 21(5 Suppl 12):83-5. PMID: 7992072
-
Hesdorffer C, Antman K, Bank A, Fetell M, Mears G, Begg M. Human MDR gene transfer in patients with advanced cancer. Hum Gene Ther. 1994 Sep; 5(9):1151-60. PMID: 7833373
-
Vogelzang NJ, Weissman LB, Herndon JE, Antman KH, Cooper MR, Corson JM, Green MR. Trimetrexate in malignant mesothelioma: A Cancer and Leukemia Group B Phase II study. J Clin Oncol. 1994 Jul; 12(7):1436-42. PMID: 8021735
-
Licht JD, Mazanet R, Loehrer PJ, Gonin R, Antman KH. Phase IV trial of daily oral etoposide in the treatment of advanced soft-tissue sarcoma. Cancer Chemother Pharmacol. 1994; 34(1):79-80. PMID: 8174207
-
Antman K, Ayash L, Elias A, Wheeler C, Schwartz G, Mazanet R, Tepler I, Schnipper LE, Frei E. High-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy: analysis by age. J Natl Cancer Inst Monogr. 1994; (16):91-4. PMID: 7528031
-
Prestifilippo J, Antman K, Berkman BJ, Kaufman D, Lantos J, Lawrence W, Levine RJ, McKenna RJ. The ethical treatment of cancer. What is right for the patient? Cancer. 1993 Nov 1; 72(9 Suppl):2816-9. PMID: 8402510
-
Lawrence W, Antman K, Freeman HP, Huber SL, Kaufman D, Lantos J, Lenhard RE, Levine RJ, McKenna RJ, Young FE. The impact of clinical trial protocols on patient care systems. Cancer. 1993 Nov 1; 72(9 Suppl):2839-41. PMID: 8402515
-
Antman K. Reimbursement issues facing patients, providers, and payers. Cancer. 1993 Nov 1; 72(9 Suppl):2842-5. PMID: 8402516
-
Murphy GP, Prestifilippo J, Antman K, Berkman BJ, Huber SL, Kaufman D, Knox WA, Lawrence W, Levine RJ, Young FE. The economic impact of therapy on cancer patients. Cancer. 1993 Nov 1; 72(9 Suppl):2862-4. PMID: 8402521
-
Chahinian AP, Antman K, Goutsou M, Corson JM, Suzuki Y, Modeas C, Herndon JE, Aisner J, Ellison RR, Leone L, et al. Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B. J Clin Oncol. 1993 Aug; 11(8):1559-65. PMID: 8336195
-
Antman K, Crowley J, Balcerzak SP, Rivkin SE, Weiss GR, Elias A, Natale RB, Cooper RM, Barlogie B, Trump DL, et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol. 1993 Jul; 11(7):1276-85. PMID: 8315425
-
Wheeler C, Strawderman M, Ayash L, Churchill WH, Bierer BE, Elias A, Gilliland DG, Antman K, Guinan EC, Eder JP, et al. Prognostic factors for treatment outcome in autotransplantation of intermediate-grade and high-grade non-Hodgkin's lymphoma with cyclophosphamide, carmustine, and etoposide. J Clin Oncol. 1993 Jun; 11(6):1085-91. PMID: 8099120
-
Sugarbaker DJ, Strauss GM, Lynch TJ, Richards W, Mentzer SJ, Lee TH, Corson JM, Antman KH. Node status has prognostic significance in the multimodality therapy of diffuse, malignant mesothelioma. J Clin Oncol. 1993 Jun; 11(6):1172-8. PMID: 8501504
-
Mentzer SJ, Antman KH, Attinger C, Shemin R, Corson JM, Sugarbaker DJ. Selected benefits of thoracotomy and chemotherapy for sarcoma metastatic to the lung. J Surg Oncol. 1993 May; 53(1):54-9. PMID: 8479198
-
Elias AD, Ayash L, Skarin AT, Wheeler C, Schwartz G, Mazanet R, Tepler I, Schnipper L, Frei E, Antman KH. High-dose combined alkylating agent therapy with autologous stem cell support and chest radiotherapy for limited small-cell lung cancer. Chest. 1993 Apr; 103(4 Suppl):433S-435S. PMID: 8096454
-
Antman KH. Natural history and epidemiology of malignant mesothelioma. Chest. 1993 Apr; 103(4 Suppl):373S-376S. PMID: 8462328
-
Ayash LJ, Elias A, Wheeler C, Tepler I, Schwartz G, Schnipper L, Frei E, Antman K. High-dose chemotherapy with autologous stem cell support for breast cancer: a review of the Dana-Farber Cancer Institute/Beth Israel Hospital experience. J Hematother. 1993; 2(4):507-11. PMID: 7916250
-
Elias AD, Ayash L, Tepler I, Wheeler C, Schwartz G, Mazanet R, Schnipper L, Frei E, Antman K. The use of G-CSF or GM-CSF mobilized peripheral blood progenitor cells (PBPC) alone or to augment marrow as hematologic support of single or multiple cycle high-dose chemotherapy. J Hematother. 1993; 2(3):377-82. PMID: 7522891
-
Antman KH, Souhami RL. High-dose chemotherapy in solid tumours. A review of published data in selected tumours with a commentary. Ann Oncol. 1993; 4 Suppl 1:29-44. PMID: 8393339
-
Antman KH. GM-CSF in marrow transplantation. Eur J Cancer. 1993; 29A Suppl 3:S2-6. PMID: 8398365
-
Antman KH. Chemotherapy of advanced sarcomas of bone and soft tissue. Semin Oncol. 1992 Dec; 19(6 Suppl 12):13-20. PMID: 1485169
-
Fine HA, Antman KH. High-dose chemotherapy with autologous bone marrow transplantation in the treatment of high grade astrocytomas in adults: therapeutic rationale and clinical experience. Bone Marrow Transplant. 1992 Oct; 10(4):315-21. PMID: 1330152
-
Southee AE, Kaplan WD, Jochelson MS, Gonin R, Dwyer JA, Antman KH, Elias AD. Gallium imaging in metastatic and recurrent soft-tissue sarcoma. J Nucl Med. 1992 Sep; 33(9):1594-9. PMID: 1517831
-
Demetri GD, Antman KH. Granulocyte-macrophage colony-stimulating factor (GM-CSF): preclinical and clinical investigations. Semin Oncol. 1992 Aug; 19(4):362-85. PMID: 1509275
-
Seiden MV, Elias A, Ayash L, Hunt M, Eder JP, Schnipper LE, Frei E, Antman KH. Pulmonary toxicity associated with high dose chemotherapy in the treatment of solid tumors with autologous marrow transplant: an analysis of four chemotherapy regimens. Bone Marrow Transplant. 1992 Jul; 10(1):57-63. PMID: 1515880
-
Ayash LJ, Wright JE, Tretyakov O, Gonin R, Elias A, Wheeler C, Eder JP, Rosowsky A, Antman K, Frei E. Cyclophosphamide pharmacokinetics: correlation with cardiac toxicity and tumor response. J Clin Oncol. 1992 Jun; 10(6):995-1000. PMID: 1588381
-
Sledge GW, Antman KH. Progress in chemotherapy for metastatic breast cancer. Semin Oncol. 1992 Jun; 19(3):317-32. PMID: 1609297
-
Singer S, Antman K, Corson JM, Eberlein TJ. Long-term salvageability for patients with locally recurrent soft-tissue sarcomas. Arch Surg. 1992 May; 127(5):548-53; discussion 553-4. PMID: 1575625
-
Antman K, Corringham R, de Vries E, Elfenbein G, Gianni AM, Gisselbrecht C, Herzig R, Juttner C, Kaizer H, Kennedy MJ, et al. Dose intensive therapy in breast cancer. Bone Marrow Transplant. 1992; 10 Suppl 1:67-73. PMID: 1355686
-
Antman K, Ayash L, Elias A, Wheeler C, Hunt M, Eder JP, Teicher BA, Critchlow J, Bibbo J, Schnipper LE, et al. A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. J Clin Oncol. 1992 Jan; 10(1):102-10. PMID: 1727912
-
Mazanet R, Antman KH. Adjuvant therapy for sarcomas. Semin Oncol. 1991 Dec; 18(6):603-12. PMID: 1775977
-
Antman KH. New developments in clinical oncology: the interdependence of bench and bedside. Cancer Res. 1991 Sep 15; 51(18 Suppl):5060s-5064s. PMID: 1679375
-
Mazanet R, Antman KH. Sarcomas of soft tissue and bone. Cancer. 1991 Aug 1; 68(3):463-73. PMID: 2065265
-
Lew MA, Kehoe K, Ritz J, Antman KH, Nadler L, Takvorian T, Mayer R, Kalish L, Finberg R. Prophylaxis of bacterial infections with ciprofloxacin in patients undergoing bone marrow transplantation. Transplantation. 1991 Mar; 51(3):630-6. PMID: 2006519
-
Ayash LJ, Antman K, Cheson BD. A perspective on dose-intensive therapy with autologous bone marrow transplantation for solid tumors. Oncology (Williston Park). 1991 Mar; 5(3):25-33; discussion 33, 36, 41. PMID: 1829944
-
Goldberg MA, Gaut CC, Schapira L, Antin JH, Ransil BJ, Antman KH, Eder JP, McGarigle CJ, Bunn HF. Erythropoietin gene regulation: from the laboratory to the bedside. Contrib Nephrol. 1991; 88:35-45; discussion 46-7. PMID: 2040197
-
Eder JP, Elias AD, Ayash L, Wheeler CA, Shea TC, Schnipper LE, Frei E, Antman KH. A phase I trial of continuous-infusion cyclophosphamide in refractory cancer patients. Cancer Chemother Pharmacol. 1991; 29(1):61-5. PMID: 1742850
-
Licht JD, Gonin R, Antman KH. Phase II trial of trimetrexate in patients with advanced soft-tissue sarcoma. Cancer Chemother Pharmacol. 1991; 28(3):223-5. PMID: 1830249
-
Schapira L, Antin JH, Ransil BJ, Antman KH, Eder JP, McGarigle CJ, Goldberg MA. Serum erythropoietin levels in patients receiving intensive chemotherapy and radiotherapy. Blood. 1990 Dec 1; 76(11):2354-9. PMID: 2257306
-
Garber JE, Liepman MK, Gelles EJ, Corson JM, Antman KH. Melanoma and soft tissue sarcoma in seven patients. Cancer. 1990 Dec 1; 66(11):2432-4. PMID: 2245401
-
Ayash LJ, Hunt M, Antman K, Nadler L, Wheeler C, Takvorian T, Elias A, Antin JH, Greenough T, Eder JP. Hepatic venoocclusive disease in autologous bone marrow transplantation of solid tumors and lymphomas. J Clin Oncol. 1990 Oct; 8(10):1699-706. PMID: 2213105
-
Antman KH. G-CSF and GM-CSF in clinical trials. Yale J Biol Med. 1990 Sep-Oct; 63(5):387-410. PMID: 1705737; PMCID: PMC2589368
-
Antman KH, Elias A, Ryan L. Ifosfamide and mesna: response and toxicity at standard- and high-dose schedules. Semin Oncol. 1990 Apr; 17(2 Suppl 4):68-73. PMID: 2110386
-
Elias A, Ryan L, Aisner J, Antman KH. Mesna, doxorubicin, ifosfamide, dacarbazine (MAID) regimen for adults with advanced sarcoma. Semin Oncol. 1990 Apr; 17(2 Suppl 4):41-9. PMID: 2110385
-
Antman K, Eder JP, Elias A, Ayash L, Shea TC, Weissman L, Critchlow J, Schryber SM, Begg C, Teicher BA, et al. High-dose thiotepa alone and in combination regimens with bone marrow support. Semin Oncol. 1990 Feb; 17(1 Suppl 3):33-8. PMID: 2106166
-
Teicher BA, Holden SA, Eder JP, Herman TS, Antman KH, Frei E. Preclinical studies relating to the use of thiotepa in the high-dose setting alone and in combination. Semin Oncol. 1990 Feb; 17(1 Suppl 3):18-32. PMID: 2106164
-
Antman KH, Elias A. Dana-Farber Cancer Institute studies in advanced sarcoma. Semin Oncol. 1990 Feb; 17(1 Suppl 2):7-15. PMID: 2106162
-
Elias AD, Eder JP, Shea T, Begg CB, Frei E, Antman KH. High-dose ifosfamide with mesna uroprotection: a phase I study. J Clin Oncol. 1990 Jan; 8(1):170-8. PMID: 2104923
-
Talcott JA, Thurber WA, Kantor AF, Gaensler EA, Danahy JF, Antman KH, Li FP. Asbestos-associated diseases in a cohort of cigarette-filter workers. N Engl J Med. 1989 Nov 2; 321(18):1220-3. PMID: 2552314
-
Flejter WL, Li FP, Antman KH, Testa JR. Recurring loss involving chromosomes 1, 3, and 22 in malignant mesothelioma: possible sites of tumor suppressor genes. Genes Chromosomes Cancer. 1989 Nov; 1(2):148-54. PMID: 2487155
-
Graves SW, Eder JP, Schryber SM, Sharma K, Brena A, Antman KH, Peters WP. Endogenous digoxin-like immunoreactive factor and digitalis-like factor associated with the hypertension of patients receiving multiple alkylating agents as part of autologous bone marrow transplantation. Clin Sci (Lond). 1989 Nov; 77(5):501-7. PMID: 2555106
-
Antman KH, Eilber FR, Shiu MH. Soft tissue sarcomas: current trends in diagnosis and management. Curr Probl Cancer. 1989 Nov-Dec; 13(6):337-67. PMID: 2689101
-
Elias A, Ryan L, Sulkes A, Collins J, Aisner J, Antman KH. Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy. J Clin Oncol. 1989 Sep; 7(9):1208-16. PMID: 2504890
-
Elias AD, Antman KH. Adjuvant chemotherapy for soft tissue sarcoma: an approach in search of an effective regimen. Semin Oncol. 1989 Aug; 16(4):305-11. PMID: 2667145
-
Antman KH, Aledort LM, Yarbro J, Wilensky G, Wojcik S, Monaco GP, Windham S. Cost-effectiveness and reimbursement in patient care. Semin Hematol. 1989 Jul; 26(3 Suppl 3):32-45. PMID: 2508228
-
Antman KH. Natural history and staging of malignant mesothelioma. Chest. 1989 Jul; 96(1 Suppl):93S-95S. PMID: 2737005
-
Shea TC, Flaherty M, Elias A, Eder JP, Antman K, Begg C, Schnipper L, Frei E, Henner WD. A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support. J Clin Oncol. 1989 May; 7(5):651-61. PMID: 2651580
-
Li FP, Dreyfus MG, Antman KH. Asbestos-contaminated nappies and familial mesothelioma. Lancet. 1989 Apr 22; 1(8643):909-10. PMID: 2564999
-
Sullivan R, Fredette JP, Socinski M, Elias A, Antman K, Schnipper L, Griffin JD. Enhancement of superoxide anion release by granulocytes harvested from patients receiving granulocyte-macrophage colony-stimulating factor. Br J Haematol. 1989 Apr; 71(4):475-9. PMID: 2540792
-
Frei E, Antman K, Teicher B, Eder P, Schnipper L. Bone marrow autotransplantation for solid tumors--prospects. J Clin Oncol. 1989 Apr; 7(4):515-26. PMID: 2647915
-
Antman KH. Summary of Institute of Medicine study of resources for clinical investigation. J Natl Cancer Inst. 1989 Mar 15; 81(6):402-3. PMID: 2918549
-
Siegel RD, Ryan LM, Antman KH. Osteosarcoma in adults. One institution's experience. Clin Orthop Relat Res. 1989 Mar; (240):261-9. PMID: 2917442
-
Antman KH, Ryan L, Elias A, Sherman D, Grier HE. Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma. J Clin Oncol. 1989 Jan; 7(1):126-31. PMID: 2491883
-
Weissmann LB, Antman KH. Incidence, presentation and promising new treatments for malignant mesothelioma. Oncology (Williston Park). 1989 Jan; 3(1):67-72; discussion 73-4, 77. PMID: 2701403
-
Mick R, Begg CB, Antman KH, Korzun AH, Frei E. Diverse prognosis in metastatic breast cancer: who should be offered alternative initial therapies? Breast Cancer Res Treat. 1989 Jan; 13(1):33-8. PMID: 2650758
-
Rosenberg AE, Garber JE, Bennett W, Bhan AK, Antman KH, Mark EJ. Epithelioid sarcoma with diffuse bone marrow metastases and associated leukemoid reaction. A case report and brief literature review. Am J Clin Pathol. 1988 Dec; 90(6):723-6. PMID: 3057863
-
Siegel RD, Ryan LM, Antman KH. Adults with Ewing's sarcoma. An analysis of 16 patients at the Dana-Farber Cancer Institute. Am J Clin Oncol. 1988 Dec; 11(6):614-7. PMID: 3189226
-
Eder JP, Antman K, Elias A, Shea TC, Teicher B, Henner WD, Schryber SM, Holden S, Finberg R, Chritchlow J, et al. Cyclophosphamide and thiotepa with autologous bone marrow transplantation in patients with solid tumors. J Natl Cancer Inst. 1988 Oct 5; 80(15):1221-6. PMID: 3138431
-
Socinski MA, Cannistra SA, Sullivan R, Elias A, Antman K, Schnipper L, Griffin JD. Granulocyte-macrophage colony-stimulating factor induces the expression of the CD11b surface adhesion molecule on human granulocytes in vivo. Blood. 1988 Aug; 72(2):691-7. PMID: 3042045
-
Antman K, Schnipper LE, Frei E. The crisis in clinical cancer research. Third-party insurance and investigational therapy. N Engl J Med. 1988 Jul 7; 319(1):46-8. PMID: 3288868
-
Shea TC, Antman KH, Eder JP, Elias A, Peters WP, Schryber S, Henner WD, Schoenfeld DA, Schnipper LE, Frei E. Malignant melanoma. Treatment with high-dose combination alkylating agent chemotherapy and autologous bone marrow support. Arch Dermatol. 1988 Jun; 124(6):878-84. PMID: 3288124
-
Socinski MA, Cannistra SA, Elias A, Antman KH, Schnipper L, Griffin JD. Granulocyte-macrophage colony stimulating factor expands the circulating haemopoietic progenitor cell compartment in man. Lancet. 1988 May 28; 1(8596):1194-8. PMID: 2897009
-
Talcott JA, Antman KH. Asbestos-related malignancy. Curr Probl Cancer. 1988 May-Jun; 12(3):135-78. PMID: 3067983
-
Antman K, Gale RP. Advanced breast cancer: high-dose chemotherapy and bone marrow autotransplants. Ann Intern Med. 1988 Apr; 108(4):570-4. PMID: 3279894
-
Licht JD, Weissmann LB, Antman K. Gastrointestinal sarcomas. Semin Oncol. 1988 Apr; 15(2):181-8. PMID: 3285480
-
Lederman GS, Recht A, Herman T, Osteen R, Corson J, Antman KH. Combined modality treatment of peritoneal mesotheliomas. NCI Monogr. 1988; (6):321-2. PMID: 3352777
-
Antman K, Shemin R, Ryan L, Klegar K, Osteen R, Herman T, Lederman G, Corson J. Malignant mesothelioma: prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women's Hospital experience over two decades, 1965-1985. J Clin Oncol. 1988 Jan; 6(1):147-53. PMID: 3335886
-
Elias AD, Antman KH. Adjuvant chemotherapy for soft-tissue sarcoma: a critical appraisal. Semin Surg Oncol. 1988; 4(1):59-65. PMID: 3281213
-
Antman KH, Elias AD. Chemotherapy of advanced soft-tissue sarcomas. Semin Surg Oncol. 1988; 4(1):53-8. PMID: 3281212
-
Henner WD, Shea TC, Furlong EA, Flaherty MD, Eder JP, Elias A, Begg C, Antman K. Pharmacokinetics of continuous-infusion high-dose thiotepa. Cancer Treat Rep. 1987 Nov; 71(11):1043-7. PMID: 3119200
-
Constable JD, Timperi R, Clapp R, Antman K, Boynton B. Vietnam veterans and soft tissue sarcoma. J Occup Med. 1987 Sep; 29(9):726. PMID: 3681503
-
Lederman GS, Recht A, Herman T, Osteen R, Corson J, Antman KH. Long-term survival in peritoneal mesothelioma. The role of radiotherapy and combined modality treatment. Cancer. 1987 Jun 1; 59(11):1882-6. PMID: 3567851
-
Talcott J, Thurber W, Gaensler E, Antman K, Li FP. Mesothelioma in manufacturers of asbestos-containing cigarette filters. Lancet. 1987 Feb 14; 1(8529):392. PMID: 2880203
-
Antman K, Eder JP, Elias A, Shea T, Peters WP, Andersen J, Schryber S, Henner WD, Finberg R, Wilmore D, et al. High-dose combination alkylating agent preparative regimen with autologous bone marrow support: the Dana-Farber Cancer Institute/Beth Israel Hospital experience. Cancer Treat Rep. 1987 Feb; 71(2):119-25. PMID: 3542208
-
Antman K, Eder JP, Frei E. High-dose chemotherapy with bone marrow support for solid tumors. Important Adv Oncol. 1987; 221-35. PMID: 2841230
-
Eder JP, Antman K, Peters W, Henner WD, Elias A, Shea T, Schryber S, Andersen J, Come S, Schnipper L, et al. High-dose combination alkylating agent chemotherapy with autologous bone marrow support for metastatic breast cancer. J Clin Oncol. 1986 Nov; 4(11):1592-7. PMID: 3534155
-
Wilson RE, Wood WC, Lerner HL, Antman K, Amato D, Corson JM, Proppe K, Harmon D, Carey R, Greenberger J, et al. Doxorubicin chemotherapy in the treatment of soft-tissue sarcoma. Combined results of two randomized trials. Arch Surg. 1986 Nov; 121(11):1354-9. PMID: 3535741
-
Antman KH. Searching for truth--from biblical to modern times. J Clin Oncol. 1986 Oct; 4(10):1441-2. PMID: 3760918
-
Henner WD, Peters WP, Eder JP, Antman K, Schnipper L, Frei E. Pharmacokinetics and immediate effects of high-dose carmustine in man. Cancer Treat Rep. 1986 Jul; 70(7):877-80. PMID: 3719578
-
Elias AD, Antman KH. Doxorubicin, ifosfamide, and dacarbazine (AID) with mesna uroprotection for advanced untreated sarcoma: a phase I study. Cancer Treat Rep. 1986 Jul; 70(7):827-33. PMID: 3087617
-
Peters WP, Eder JP, Henner WD, Schryber S, Wilmore D, Finberg R, Schoenfeld D, Bast R, Gargone B, Antman K, et al. High-dose combination alkylating agents with autologous bone marrow support: a Phase 1 trial. J Clin Oncol. 1986 May; 4(5):646-54. PMID: 3517240
-
Gibas Z, Li FP, Antman KH, Bernal S, Stahel R, Sandberg AA. Chromosome changes in malignant mesothelioma. Cancer Genet Cytogenet. 1986 Feb 15; 20(3-4):191-201. PMID: 3943062
-
Antman KH. Asbestos-related malignancy. Crit Rev Oncol Hematol. 1986; 6(3):287-309. PMID: 3542255
-
Kaye JA, Wang AM, Joachim CL, Seltzer SE, Cibas E, Skarin A, Antman KH. Malignant mesothelioma with brain metastases. Am J Med. 1986 Jan; 80(1):95-7. PMID: 3942156
-
Antman KH, Osteen RT, Klegar KL, Amato DA, Pomfret EA, Larson DA, Corson JM. Early peritoneal mesothelioma: a treatable malignancy. Lancet. 1985 Nov 2; 2(8462):977-81. PMID: 2414612
-
Antman K, Amato D, Wood W, Carson J, Suit H, Proppe K, Carey R, Greenberger J, Wilson R, Frei E. Selection bias in clinical trials. J Clin Oncol. 1985 Aug; 3(8):1142-7. PMID: 4020412
-
Antman KH, Montella D, Rosenbaum C, Schwen M. Phase II trial of ifosfamide with mesna in previously treated metastatic sarcoma. Cancer Treat Rep. 1985 May; 69(5):499-504. PMID: 3924401
-
Kobzik L, Antman KH, Warhol MJ. The distinction of mesothelioma from adenocarcinoma in malignant effusions by electron microscopy. Acta Cytol. 1985 May-Jun; 29(3):219-25. PMID: 3859121
-
Antman KH, Corson JM. Benign and malignant pleural mesothelioma. Clin Chest Med. 1985 Mar; 6(1):127-40. PMID: 3891207
-
Antman K, Pomfret E, Karp G, Skarin A, Canellos G. Phase II trial of etoposide in previously treated small cell carcinoma of the lung. Cancer Treat Rep. 1984 Nov; 68(11):1413-4. PMID: 6094004
-
Antman KH, Nadler L, Mark EJ, Montella DL, Kirkpatrick P, Halpern J. Primary Kaposi's sarcoma of the lung in an immunocompetent 32-year-old heterosexual white man. Cancer. 1984 Oct 15; 54(8):1696-8. PMID: 6478408
-
Antman KH, Ruxer RL, Aisner J, Vawter G. Mesothelioma following Wilms' tumor in childhood. Cancer. 1984 Jul 15; 54(2):367-9. PMID: 6327010
-
Antman K, Suit H, Amato D, Corson J, Wood W, Proppe K, Harmon D, Carey R, Greenberger J, Blum R, et al. Preliminary results of a randomized trial of adjuvant doxorubicin for sarcomas: lack of apparent difference between treatment groups. J Clin Oncol. 1984 Jun; 2(6):601-8. PMID: 6374055
-
Antman K, Cohen S, Dimitrov NV, Green M, Muggia F. Malignant mesothelioma of the tunica vaginalis testis. J Clin Oncol. 1984 May; 2(5):447-51. PMID: 6726298
-
Wilson RE, Antman KH, Brodsky G, Greenberger JS. Tumor-cell heterogeneity in soft tissue sarcomas as defined by chemoradiotherapy. Cancer. 1984 Mar 15; 53(6):1420-5. PMID: 6692332
-
Antman KH, Corson JM, Li FP, Greenberger J, Sytkowski A, Henson DE, Weinstein L. Malignant mesothelioma following radiation exposure. J Clin Oncol. 1983 Nov; 1(11):695-700. PMID: 6668488
-
Grant DC, Seltzer SE, Antman KH, Finberg HJ, Koster K. Computed tomography of malignant pleural mesothelioma. J Comput Assist Tomogr. 1983 Aug; 7(4):626-32. PMID: 6863663
-
Antman KH, Pomfret EA, Aisner J, MacIntyre J, Osteen RT, Greenberger JS. Peritoneal mesothelioma: natural history and response to chemotherapy. J Clin Oncol. 1983 Jun; 1(6):386-91. PMID: 6668506
-
Antman KH, Blum RH, Wilson RE, Corson JM, Greenberger JS, Amato DA, Canellos GP, Frei E. Survival of patients with localized high-grade soft tissue sarcoma with multimodality therapy. A matched control study. Cancer. 1983 Feb 1; 51(3):396-401. PMID: 6821825
-
Antman KH, Corson J, Greenberger J, Wilson R. Multimodality therapy in the management of angiosarcoma of the breast. Cancer. 1982 Nov 15; 50(10):2000-3. PMID: 6889910
-
Nauta RJ, Osteen RT, Antman KH, Koster JK. Clinical staging and the tendency of malignant pleural mesotheliomas to remain localized. Ann Thorac Surg. 1982 Jul; 34(1):66-70. PMID: 7092403
-
Devereux DF, Wilson RE, Carson JM, Antman KH, Greenberger JS. Surgical treatment of low grade soft tissue sarcomas. Am J Surg. 1982 Apr; 143(4):490-4. PMID: 7072914
-
Whitley NO, Brenner DE, Antman KH, Grant D, Aisner J. CT of peritoneal mesothelioma: analysis of eight cases. AJR Am J Roentgenol. 1982 Mar; 138(3):531-5. PMID: 6978005
-
Antman KH, Parker LM, Goldstein JD, Skarin AT, D'Orsi CJ. Acute renal failure following intravenous pyelography (IVP) in a patient with diffuse hypergammaglobulinemia: a case report. Med Pediatr Oncol. 1982; 10(3):289-94. PMID: 7045616
-
Gordon W, Antman KH, Greenberger JS, Weichselbaum RR, Chaffey JT. Radiation therapy in the management of patients with mesothelioma. Int J Radiat Oncol Biol Phys. 1982 Jan; 8(1):19-25. PMID: 6174494
-
Antman KH. Clinical presentation and natural history of benign and malignant mesothelioma. Semin Oncol. 1981 Sep; 8(3):313-20. PMID: 7280715
-
Karp G, Antman K, Canellos G. VP-16-213. A phase II trial using a weekly schedule. Cancer Clin Trials. 1981; 4(4):465-7. PMID: 7318129
-
Nadler LM, Stashenko P, Hardy R, Kaplan WD, Button LN, Kufe DW, Antman KH, Schlossman SF. Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen. Cancer Res. 1980 Sep; 40(9):3147-54.View Related Profiles. PMID: 7427932
-
Antman KH. Current concepts: malignant mesothelioma. N Engl J Med. 1980 Jul 24; 303(4):200-2. PMID: 6155613
-
Antman KH, Livingston DM. Intracellular neutralization of SV40 tumor antigens following microinjection of specific antibody. Cell. 1980 Mar; 19(3):627-35. PMID: 6244892
-
Antman KH, Blum RH, Greenberger JS, Flowerdew G, Skarin AT, Canellos GP. Multimodality therapy for malignant mesothelioma based on a study of natural history. Am J Med. 1980 Mar; 68(3):356-62. PMID: 7361805
-
Antman KH, Skarin AT, Mayer RJ, Hargreaves HK, Canellos GP. Microangiopathic hemolytic anemia and cancer: a review. Medicine (Baltimore). 1979 Sep; 58(5):377-84. PMID: 481196
This graph shows the total number of publications by year, by first, middle/unknown,
or last author.
| Year | Publications |
|---|
| 1980 | 4 |
| 1981 | 2 |
| 1982 | 6 |
| 1983 | 4 |
| 1984 | 6 |
| 1985 | 5 |
| 1986 | 9 |
| 1987 | 6 |
| 1988 | 14 |
| 1989 | 17 |
| 1990 | 10 |
| 1991 | 8 |
| 1992 | 10 |
| 1993 | 15 |
| 1994 | 5 |
| 1995 | 5 |
| 1996 | 4 |
| 1997 | 12 |
| 1998 | 8 |
| 1999 | 12 |
| 2000 | 5 |
| 2001 | 9 |
| 2002 | 6 |
| 2003 | 3 |
| 2004 | 1 |
| 2005 | 1 |
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 2 |
| 2015 | 2 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 3 |
2011 Institute of Medicine:
Member
2008 American Society of Clinical Oncology :
Distinguished Service Award for Scientific Leadership
2001 American Association of Professors:
Member
1997 American Association for the Advancement of Science:
Elected to Fellowship
1996 Jeffrey Gottlieb Memorial Award
1994 Voted by Medical Residents, Columbia-Presbyterian Medical Center:
Senior Faculty Teacher of the Year
1981 American Cancer Society:
Junior Faculty Clinical Fellowship
1980 National Cancer Institute:
Research Fellowship